# Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT00726986** · PHASE2 · TERMINATED · sponsor: **Afshin Dowlati, MD** · enrollment: 18 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** etoposide
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00726986
- **Lead sponsor:** Afshin Dowlati, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Extreme toxicity
- **Last updated:** 2014-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00726986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00726986, "Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00726986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*